Beijing Winsunny Pharmaceutical CO.LTD (601089) — Capital Reinvestment Ratio
Beijing Winsunny Pharmaceutical CO.LTD (601089) has a Capital Reinvestment Ratio of 0.57x as of December 2024, meaning it reinvests 1% of its operating cash flow (CN¥690.75 Million) in capital expenditures (CN¥391.52 Million). See 601089 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Beijing Winsunny Pharmaceutical CO.LTD Capital Reinvestment Ratio (2020–2024)
This chart tracks Beijing Winsunny Pharmaceutical CO.LTD's Capital Reinvestment Ratio across 5 annual periods.
Annual Capital Reinvestment Ratio for Beijing Winsunny Pharmaceutical CO.LTD (2020–2024)
Year-by-year Capital Reinvestment Ratio for Beijing Winsunny Pharmaceutical CO.LTD from 2020 to 2024. For live market cap and broader valuation context, see Beijing Winsunny Pharmaceutical CO.LTD (601089) market capitalisation.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.57x | CN¥690.75 Million | CN¥391.52 Million | ▼ -13.9% |
| 2023 | 0.66x | CN¥555.90 Million | CN¥366.08 Million | ▲ +220.9% |
| 2022 | 0.21x | CN¥659.76 Million | CN¥135.40 Million | ▼ -43.8% |
| 2021 | 0.37x | CN¥528.02 Million | CN¥192.97 Million | ▼ -16.4% |
| 2020 | 0.44x | CN¥386.65 Million | CN¥168.96 Million | — |